Trial Set in NEC Multidistrict Litigation Against Reckitt Benckiser's Mead Johnson Led by Levin Papantonio

Core Viewpoint - Mead Johnson, a subsidiary of Reckitt Benckiser, is involved in a significant trial regarding its infant formula product Enfamil, which is linked to necrotizing enterocolitis (NEC) in premature infants, scheduled for July 6, 2026 [1] Group 1 - The trial is part of the US Multidistrict Litigation (MDL) concerning the health risks associated with Enfamil [1] - NEC is described as a severe intestinal disease that can lead to tissue death and life-threatening infections in premature babies [1] - Andy Childers, an attorney from Levin Papantonio, is serving as the Plaintiffs' Co-Lead Counsel in the MDL [1]